Znanstveni rad - Izvorni znanstveni rad
A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera®) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL)
BioDrugs, 34 (2020), 2; 171-181. https://doi.org/10.1007/s40259-019-00398-7

Sharman, Jeff P.; Liberati, Anna Marina; Ishizawa, Kenichi; Khan, Tahira; Robbins, Jeffery; Alcasid, Ann; Rosenberg, Julie Ann; Aurer, Igor

Citirajte ovaj rad

Sharman, J. P., Liberati, A. M., Ishizawa, K., Khan, T., Robbins, J., Alcasid, A. ... Aurer, I. (2020). A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera®) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL). BioDrugs, 34. (2), 171-181. doi: 10.1007/s40259-019-00398-7

Sharman, Jeff P., et al. "A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera®) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL)." BioDrugs, vol. 34, br. 2, 2020, str. 171-181. https://doi.org/10.1007/s40259-019-00398-7

Sharman, Jeff P., Anna Marina Liberati, Kenichi Ishizawa, Tahira Khan, Jeffery Robbins, Ann Alcasid, Julie Ann Rosenberg i Igor Aurer. "A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera®) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL)." BioDrugs 34, br. 2 (2020): 171-181. https://doi.org/10.1007/s40259-019-00398-7

Sharman, J. P., et al. (2020) 'A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera®) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL)', BioDrugs, 34(2), str. 171-181. doi: 10.1007/s40259-019-00398-7

Sharman JP, Liberati AM, Ishizawa K, Khan T, Robbins J, Alcasid A, i sur.. A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera®) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL). BioDrugs [Internet]. 04.2020. [pristupljeno 29.02.2024.];34(2):171-181. doi: 10.1007/s40259-019-00398-7

J. P. Sharman, et al., "A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera®) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL)", BioDrugs, vol. 34, br. 2, str. 171-181, Travanj 2020. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:921728. [Citirano: 29.02.2024.]

Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.